Systematic review and network meta-analysis: efficacy of drugs for functional dyspepsia

Alexander C Ford, Paul Moayyedi, Christopher J Black, Yuhong Yuan, Sajesh K Veettil, Sanjiv Mahadeva, Kirati Kengkla, Nathorn Chaiyakunapruk, Yeong Yeh Lee, Alexander C Ford, Paul Moayyedi, Christopher J Black, Yuhong Yuan, Sajesh K Veettil, Sanjiv Mahadeva, Kirati Kengkla, Nathorn Chaiyakunapruk, Yeong Yeh Lee

Abstract

Background: Functional dyspepsia (FD) is a relapsing and remitting condition affecting between 5% and 10% of people. Efficacious therapies are available, but their relative efficacy is unknown.

Aim: To perform a systematic review with network meta-analysis to resolve this uncertainty.

Methods: We searched the medical literature through July 2020 for randomised controlled trials (RCTs) assessing efficacy of drugs for adults with FD, compared with each other, or placebo. Trials reported a dichotomous assessment of symptom status after completion of therapy. We pooled data using a random effects model. Efficacy was reported as a pooled relative risk (RR) of remaining symptomatic with a 95% confidence interval (CI) to summarise efficacy of each comparison tested. Relative ranking was assessed with surface under the cumulative ranking curve (SUCRA) probabilities.

Results: We identified 71 eligible RCTs (19 243 participants). Tricyclic antidepressants (TCAs) were ranked second for efficacy (RR of remaining symptomatic = 0.71; 95% CI 0.58-0.87, SUCRA 0.87), and first when only low risk of bias trials were included. Most RCTs that used TCAs recruited patients who were refractory to other drugs included in the network. Although sulpiride or levosulpiride were ranked first for efficacy (RR = 0.49; 95% CI 0.36-0.69, SUCRA 0.99), trial quality was low and only 86 patients received active therapy. TCAs were more likely to cause adverse events than placebo.

Conclusions: TCAs, histamine-2 receptor antagonists, standard- and low-dose proton pump inhibitors, sulpiride or levosulpiride, itopride and acotiamide were all more efficacious than placebo for FD.

© 2020 John Wiley & Sons Ltd.

References

REFERENCES

    1. Drossman DA, Hasler WL. Rome IV-functional GI disorders: disorders of gut-brain interaction. Gastroenterology. 2016;150:1257-1261.
    1. Stanghellini V, Chan FKL, Hasler WL, et al. Gastroduodenal disorders. Gastroenterology. 2016;150:1380-1392.
    1. Sperber AD, Bangdiwala SI, Drossman DA, et al. Worldwide prevalence and burden of functional gastrointestinal disorders, results of Rome Foundation global study. Gastroenterology. 2020.
    1. Ford AC, Forman D, Bailey AG, Axon ATR, Moayyedi P. Initial poor quality of life and new onset of dyspepsia: results from a longitudinal 10-year follow-up study. Gut. 2007;56:321-327.
    1. Aro P, Talley NJ, Johansson SE, Agreus L, Ronkainen J. Anxiety Is linked to new-onset dyspepsia in the Swedish population: a 10-year follow-up study. Gastroenterology. 2015;148:928-937.
    1. Aro P, Talley NJ, Ronkainen J, et al. Anxiety is associated with uninvestigated and functional dyspepsia (Rome III criteria) in a Swedish population-based study. Gastroenterology. 2009;137:94-100.
    1. Gracie DJ, Bercik P, Morgan DG, et al. No increase in prevalence of somatization in functional vs organic dyspepsia: a cross-sectional survey. Neurogastroenterol Motil. 2015;27:1024-1031.
    1. Camilleri M, Dubois D, Coulie B, et al. Prevalence and socioeconomic impact of upper gastrointestinal disorders in the United States: results of the US Upper Gastrointestinal Study. Clin Gastroenterol Hepatol. 2005;3:543-552.
    1. Brook RA, Kleinman NL, Choung RS, Melkonian AK, Smeeding JE, Talley NJ. Functional dyspepsia impacts absenteeism and direct and indirect costs. Clin Gastroenterol Hepatol. 2010;8:498-503.
    1. Lacy BE, Everhart K, Crowell MD. Functional dyspepsia: clinical symptoms, psychological findings, and GCSI scores. Dig Dis Sci. 2019;64:1281-1287.
    1. Lacy BE, Yu J, Crowell MD. Medication risk-taking behavior in functional dyspepsia patients. Clin Transl Gastroenterol. 2015;6:e69.
    1. Lacy BE, Weiser KT, Kennedy AT, Crowell MD, Talley NJ. Functional dyspepsia: the economic impact to patients. Aliment Pharmacol Ther. 2013;38:170-177.
    1. Berger M, Gray JA, Roth BL. The expanded biology of serotonin. Annu Rev Med. 2009;60:355-366.
    1. Gershon MD, Wade PR, Kirchgessner AL, Tamir H. 5-HT receptor subtypes outside the central nervous system. Roles in the physiology of the gut. Neuropsychopharmacology. 1990;3:385-395.
    1. Mansi C, Borro P, Giacomini M, et al. Comparative effects of levosulpiride and cisapride on gastric emptying and symptoms in patients with functional dyspepsia and gastroparesis. Aliment Pharmacol Ther. 2000;14:561-569.
    1. Pinto-Sanchez MI, Yuan Y, Hassan A, Bercik P, Moayyedi P. Proton pump inhibitors for functional dyspepsia. Cochrane Database Syst Rev. 2017;11:CD011194.
    1. Pittayanon R, Yuan Y, Bollegala NP, et al. Prokinetics for functional dyspepsia: a systematic review and meta-analysis of randomized control trials. Am J Gastroenterol. 2019;114:233-243.
    1. Pittayanon R, Yuan Y, Bollegala NP, Khanna R, Leontiadis GI, Moayyedi P. Prokinetics for functional dyspepsia. Cochrane Database Syst Rev. 2018;10:CD009431.
    1. Ford AC, Luthra P, Tack J, Boeckxstaens GE, Moayyedi P, Talley NJ. Efficacy of psychotropic drugs in functional dyspepsia: systematic review and meta-analysis. Gut. 2017;66:411-420.
    1. Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162:777-784.
    1. Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions: version 5.1.0 [updated March 2011]. http://handbook-5-1cochraneorg/2011
    1. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-188.
    1. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557-560.
    1. Chaimani A, Higgins JP, Mavridis D, Spyridonos P, Salanti G. Graphical tools for network meta-analysis in STATA. PLoS One. 2013;8:e76654.
    1. Veroniki AA, Vasiliadis HS, Higgins JP, Salanti G. Evaluation of inconsistency in networks of interventions. Int J Epidemiol. 2013;42:332-345.
    1. Higgins JP, Jackson D, Barrett JK, Lu G, Ades AE, White IR. Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies. Res Synth Methods. 2012;3:98-110.
    1. Dias S, Welton NJ, Caldwell DM, Ades AE. Checking consistency in mixed treatment comparison meta-analysis. Stat Med. 2010;29:932-944.
    1. Salanti G, Ades AE, Ioannidis JP. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol. 2011;64:163-171.
    1. Dechartres A, Altman DG, Trinquart L, Boutron I, Ravaud P. Association between analytic strategy and estimates of treatment outcomes in meta-analyses. JAMA. 2014;312:623-630.
    1. Puhan MA, Schunemann HJ, Murad MH, et al. A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis. BMJ. 2014;349:g5630.
    1. Delattre M, Malesky M, Prinzie A. Symptomatic treatment of non-ulcer dyspepsia with cimetidine. Curr Ther Res. 1985;37:980-991.
    1. Kelbaek H, Linde J, Eriksen J, Mungaard S, Moesgaard F, Bonnevie O. Controlled clinical trial of treatment with cimetidine for non-ulcer dyspepsia. Acta Med Scand. 1985;217:281-287.
    1. Nesland AA, Berstad A. Effect of cimetidine in patients with non-ulcer dyspepsia and erosive prepyloric changes. Scand J Gastroenterol. 1985;20:629-635.
    1. Olubuyide IO, Ayoola EA, Okubanjo AO, Atoba MA. Non-ulcer dyspepsia in Nigerians clinical and therapeutic results. Scand J Gastroenterol Suppl. 1986;124:83-87.
    1. Saunders JH, Oliver RJ, Higson DL. Dyspepsia: Incidence of a non-ulcer disease in a controlled trial of ranitidine in general practice. BMJ. 1986;292:665-668.
    1. Gotthard R, Bodemar G, Brodin U, Jonsson KA. Treatment with cimetidine, antacid, or placebo in patients with dyspepsia of unknown origin. Scand J Gastroenterol. 1988;23:7-18.
    1. Hadi S. Clinical investigation of ranitidine in patients with gastritis. Clin Ther. 1989;11:590-594.
    1. Singal AK, Kumar A, Broor SL. Cimetidine in the treatment of non-ulcer dyspepsia: results of a randomized double-blind, placebo-controlled study. Curr Med Res Opin. 1989;11:390-397.
    1. Muller P, Hotz J, Franz E, Simon B. Ranitidine in the treatment of non-ulcer dyspepsia. A placebo-controlled study in the Federal Republic of Germany. Arzneimittelforschung. 1994;44:1130-1132.
    1. Hansen JM, Bytzer P, Schaffalitzky de Muckadell OB. Placebo-controlled trial of cisapride and nizatidine in unselected patients with functional dyspepsia. Am J Gastroenterol. 1998;93:368-374.
    1. Kato M, Watanabe M, Konishi S, et al. Randomized, double-blind, placebo-controlled crossover trial of famotidine in patients with functional dyspepsia. Aliment Pharmacol Ther. 2005;21:27-31.
    1. Talley NJ, Tack JF, Kowalski DL, Borton MA, Barve A. A novel acetylcholine esterase inhibitor acotiamide hydrochloride (YM443) in functional dyspepsia: Efficacy in a randomized, double-blind, placebo-controlled dose ranging trial. Gastroenterology. 2008;134:A-157.
    1. Kusunoki H, Haruma K, Manabe N, et al. Therapeutic efficacy of acotiamide in patients with functional dyspepsia based on enhanced postprandial gastric accommodation and emptying: randomized controlled study evaluation by real-time ultrasonography. Neurogastroenterol Motil. 2012;24:540-545.
    1. Tack JF, Stanghellini V, Holtmann G, et al. Efficacy and safety study of acotiamide (Z-338) in European patients with functional dyspepsia. Gastroenterology. 2011;140:S-805.
    1. Matsueda K, Hongo M, Tack J, Aoki H, Saito Y, Kato H. Clinical trial: dose-dependent therapeutic efficacy of acotiamide hydrochloride (Z-338) in patients with functional dyspepsia - 100 mg t.i.d. is an optimal dosage. Neurogastroenterol Motil. 2010;22:618-e173.
    1. Matsueda K, Hongo M, Tack J, Saito Y, Kato H. A placebo-controlled trial of acotiamide for meal-related symptoms of functional dyspepsia. Gut. 2012;61:821-828.
    1. Holtmann G, Talley NJ, Liebregts T, Adam B, Parow C. A placebo-controlled trial of itopride in functional dyspepsia. N Engl J Med. 2006;354:832-840.
    1. Talley NJ, Tack J, Ptak T, Gupta R, Giguere M. Itopride in functional dyspepsia: results of two phase III multicentre, randomised, double-blind, placebo-controlled trials. Gut. 2008;57:740-746.
    1. Wong Z, Nadirah Daud U, Naidu J, et al. Randomised, double-blind placebo controlled trial assessing the efficacy of itopride in postprandial distress syndrome (PDS): a pilot study. J Gastroenterol Hepatol. 2014;29:124-125.
    1. Mo JZ, Li DG, Jiang JH, et al. A multi-center clinical trial of itopride hydrochloride in the treatment of functional dyspepsia. Chin J New Drugs. 2003;12:467-469.
    1. Zhou L-Y, Li B-Q, Lin S-R, et al. [A multicenter clinical trial on itopride hydrochloride for treatment of functional dyspepsia]. Chinese. J Clin Pharmacol. 2000;16:403-407.
    1. Zhu CQ, Mao YM, Zeng MD, et al. A clinical study of hydrochloride itopride in the treatment of functional dyspepsia. J Chin Pharm Univ. 2005;6:580-583.
    1. Sun J, Zhang CL, Chu Y, Yuan YZ, Li ZS, Liu XG. A multicenter, double-blind, randomized and controlled trial of itopride hydrochloride in treatment of functional dyspepsia Shanghai Med J. 2003;26:227-229.
    1. Li YH, Gong PL, Hou XH, et al. Itopride in treatment of 104 patients with functional dyspepsia: a randomized, double blind controlled clinical trial. Chin J New Drugs Clin Remedies. 2005;7:524-528.
    1. Sawant P, Das HS, Desai N, Kalokhe S, Patil S. Comparative evaluation of the efficacy and tolerability of itopride hydrochloride and domperidone in patients with non-ulcer dyspepsia. J Assoc Physicians India. 2004;52:626-628.
    1. Peura DA, Kovacs TO, Metz DC, Siepman N, Pilmer BL, Talley NJ. Lansoprazole in the treatment of functional dyspepsia: two double-blind, randomized, placebo-controlled trials. Am J Med. 2004;116:740-748.
    1. Wong WM, Wong BC, Hung WK, et al. Double blind, randomised, placebo controlled study of four weeks of lansoprazole for the treatment of functional dyspepsia in Chinese patients. Gut. 2002;51:502-506.
    1. Talley NJ, Meineche-Schmidt V, Pare P, et al. Efficacy of omeprazole in functional dyspepsia: double-blind, randomized, placebo-controlled trials (the Bond and Opera studies). Aliment Pharmacol Ther. 1998;12:1055-1065.
    1. Bolling-Sternevald E, Lauritsen K, Aalykke C, et al. Effect of profound acid suppression in functional dyspepsia: a double-blind, randomized, placebo-controlled trial. Scand J Gastroenterol. 2002;37:1395-1402.
    1. van Zanten SV, Armstrong D, Chiba N, et al. Esomeprazole 40 mg once a day in patients with functional dyspepsia: the randomized, placebo-controlled "ENTER" trial. Am J Gastroenterol. 2006;101:2096-2106.
    1. Talley NJ, Vakil N, Lauritsen K, et al. Randomized-controlled trial of esomeprazole in functional dyspepsia patients with epigastric pain or burning: does a 1-week trial of acid suppression predict symptom response? Aliment Pharmacol Ther. 2007;26:673-682.
    1. Majewski M, Sarosiek I, Cooper CJ, et al. Gastric pH and therapeutic responses to esomeprazole in patients with functional dyspepsia: potential clinical implications. Am J Med Sci. 2016;352:582-592.
    1. Gerson LB, Triadafilopoulos G. A prospective study of oesophageal 24-h ambulatory pH monitoring in patients with functional dyspepsia. Dig Liver Dis. 2005;37:87-91.
    1. van Rensburg C, Berghöfer P, Enns R, et al. Efficacy and safety of pantoprazole 20 mg once daily treatment in patients with ulcer-like functional dyspepsia. Curr Med Res Opin. 2008;24:2009-2018.
    1. Fletcher J, Derakhshan MH, Jones GR, Wirz AA, McColl KE. BMI is superior to symptoms in predicting response to proton pump inhibitor: randomised trial in patients with upper gastrointestinal symptoms and normal endoscopy. Gut. 2011;60:442-448.
    1. Hengels KJ. Therapeutic efficacy of 15mg lansoprazole mane in 269 patients suffering from non-ulcer dyspepsia (NUD): a multicentre, randomised, double-blind study. Gut. 1998;43:A89.
    1. Tominaga K, Suzuki H, Umegaki E, et al. Rabeprazole improves the symptoms of functional dyspepsia - a double-blind randomized placebo-controlled multi-center trial in Japan: the CAESAR study. Gastroenterology. 2010;138:S-55.
    1. Suzuki H, Kusunoki H, Kamiya T, et al. Effect of lansoprazole on the epigastric symptoms of functional dyspepsia (ELF study): a multicentre, prospective, randomized, double-blind, placebo-controlled clinical trial. United European Gastroenterol J. 2013;1:445-452.
    1. Braak B, Klooker TK, Wouters MM, Lei A, van den Wijngaard RM, Boeckxstaens GE. Randomised clinical trial: the effects of amitriptyline on drinking capacity and symptoms in patients with functional dyspepsia, a double-blind placebo-controlled study. Aliment Pharmacol Ther. 2011;34:638-648.
    1. Cheong PK, Ford AC, Cheung CKY, et al. Low-dose imipramine for refractory functional dyspepsia: a randomised, double-blind, placebo-controlled trial. Lancet Gastroenterol Hepatol. 2018;3:837-844.
    1. Miwa H, Nagahara A, Tominaga K, et al. Efficacy of the 5-HT 1 A agonist tandospirone citrate in improving symptoms of patients with functional dyspepsia: a randomized controlled trial. Am J Gastroenterol. 2009;104:2779-2787.
    1. Tack J, Janssen P, Masaoka T, Farre R, van Oudenhove L. Efficacy of buspirone, a fundus-relaxing drug, in patients with functional dyspepsia. Clin Gastroenterol Hepatol. 2012;10:1239-1245.
    1. Tack J, Van Den Elzen B, Tytgat G, et al. A placebo-controlled trial of the 5-HT1A agonist R-137696 on symptoms, visceral hypersensitivity and on impaired accommodation in functional dyspepsia. Neurogastroenterol Motil. 2009;21:619-626, e23-4.
    1. Arienti V, Corazza GR, Sorge M, et al. The effects of levosulpiride on gastric and gall-bladder emptying in functional dyspepsia. Aliment Pharmacol Ther. 1994;8:631-638.
    1. Hui W-M, Lam S-K, Lok AS-F, Ng MM-T, Wong K-L, Fok K-H. Sulpiride improves functional dyspepsia: a double-blind controlled study. J Gastroenterol Hepatol. 1986;1:391-399.
    1. Song CW, Chun HJ, Kim CD, Ryu HS, Choe JG, Hyun JH. Effects of levosulpiride in patients with functional dyspepsia accompanied by delayed gastric emptying. Korean J Intern Med. 1998;13:15-21.
    1. Vakil N, Laine L, Talley NJ, et al. Tegaserod treatment for dysmotility-like functional dyspepsia: results of two randomized, controlled trials. Am J Gastroenterol. 2008;103:1906-1919.
    1. Seno H, Nakase H, Chiba T. Usefulness of famotidine in functional dyspepsia patient treatment: comparison among prokinetic, acid suppression and antianxiety therapies. Aliment Pharmacol Ther. 2005;21:32-36.
    1. Kinoshita Y, Hashimoto T, Kawamura A, et al. Effects of famotidine, mosapride and tandospirone for treatment of functional dyspepsia. Aliment Pharmacol Ther. 2005;21:37-41.
    1. Tan VP, Cheung TK, Wong WM, Pang R, Wong BC. Treatment of functional dyspepsia with sertraline: a double-blind randomized placebo-controlled pilot study. World J Gastroenterol. 2012;18:6127-6133.
    1. Vankerkhoven L, Laheij R, Aparicio N, et al. Effect of the antidepressant venlafaxine in functional dyspepsia: a randomized, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol. 2008;6:746-752.
    1. Talley NJ, Locke GR, Saito YA, et al. Effect of amitriptyline and escitalopram on functional dyspepsia: a multi-center, randomized, controlled study. Gastroenterology. 2015;149:340-349.
    1. Tack J, Ly HG, Carbone F, et al. Mirtazapine in patients with functional dyspepsia patients and weight loss. Clin Gastroenterol Hepatol. 2016;14:385-392.
    1. Hallerback BI, Bommelaer G, Bredberg E, et al. Dose finding study of mosapride in functional dyspepsia: a placebo-controlled, randomized study. Aliment Pharmacol Ther. 2002;16:959-967.
    1. Iwakiri R, Tominaga K, Furuta K, et al. Randomised clinical trial: rabeprazole improves symptoms in patients with functional dyspepsia in Japan. Aliment Pharmacol Ther. 2013;38:729-740.
    1. Blum AL, Arnold R, Stolte M, Fischer M, Koelz HR. Short course acid suppressive treatment for patients with functional dyspepsia: results depend on Helicobacter pylori status. The Frosch Study Group. Gut. 2000;47:473-480.
    1. Dillon JF, Finch PJ, Baxter G. A comparison of lansoprazole vs ranitidine in the treatment of functional ulcer-like dyspepsia as defined by the Rome II criteria. Gut. 2004;53:A285.
    1. Jiang Q, Ding X, Zhang S, Wang H, Yu X, Xie S. Comparison of mosapride and pantoprazole in treating functional dyspepsia. Chin J Gastroenterol. 2011;16:254-263.
    1. Hsu Y-C, Liou J-M, Yang T-H, et al. Proton pump inhibitor versus prokinetic therapy in patients with functional dyspepsia: is therapeutic response predicted by Rome III subgroups? J Gastroenterol. 2011;46:183-190.
    1. Kamiya T, Shikano M, Kubota E, et al. A multicenter randomized trial comparing rabeprazole and itopride in patients with functional dyspepsia in Japan: The NAGOYA study. J Clin Biochem Nutr. 2017;60:130-135.
    1. Otaka M, Jin M, Odashima M, et al. New strategy of therapy for functional dyspepsia using famotidine, mosapride and amitriptyline. Aliment Pharmacol Ther. 2005;21:42-46.
    1. Amarapurkar DN, Rane P. Randomised, double-blind, comparative study to evaluate the efficacy and safety of ganaton (itopride hydrochloride) and mosapride citrate in the management of functional dyspepsia. J Indian Med Assoc. 2004;102:735-737, 760.
    1. Chen SY, Wang JY, Zhu CW, et al. [A randomized controlled multi-center clinical trial on mosapride in the treatment of functional dyspepsia]. Zhonghua Liu Xing Bing Xue Za Zhi. 2004;25:165-168.
    1. Carbone F, Vandenberghe A, Holvoet L, Vanuytsel T, Jones MP, Tack JF. The therapeutic outcome of itopride in functional dyspepsia postprandial distress syndrome: a double-blind randomized, multicenter, placebo-controlled study. Gastroenterology. 2018;154:S-91.
    1. Jiang SM, Jia L, Liu J, Shi MM, Xu MZ. Beneficial effects of antidepressant mirtazapine in functional dyspepsia patients with weight loss. World J Gastroenterol. 2016;22:5260-5266.
    1. Kaosombatwattana U, Pongprasobchai S, Limsrivilai J, Maneerattanaporn M, Leelakusolvong S, Tanwandee T. Efficacy and safety of nortriptyline in functional dyspepsia in Asians: a randomized double-blind placebo-controlled trial. J Gastroenterol Hepatol. 2018;33:411-417.
    1. Liu J, Jia L, Jiang SM, Zhou WC, Liu Y, Xu J. Effects of low-dose amitriptyline on epigastric pain syndrome in functional dyspepsia patients. Dig Dis Sci. 2020.
    1. Singh H, Bala R, Kaur K. Efficacy and tolerability of levosulipride, domperidone and metoclopramide in patients with non-ulcer functional dyspepsia: a comparative analysis. J Clin Diagn Res. 2015;9:FC09-FC12.
    1. Barberio B, Mahadeva S, Black CJ, Savarino EV, Ford AC. Systematic review with meta-analysis: global prevalence of uninvestigated dyspepsia according to the Rome criteria. Aliment Pharmacol Ther. 2020;52:762-773.
    1. Gallego D, Ortega O, Arenas C, López I, Mans E, Clavé P. The effect of levosulpiride on in vitro motor patterns in the human gastric fundus, antrum, and jejunum. Neurogastroenterol Motil. 2016;28:879-890.
    1. Bouras EP, Talley NJ, Camilleri M, et al. Effects of amitriptyline on gastric sensorimotor function and postprandial symptoms in healthy individuals: a randomized, double-blind, placebo-controlled trial. Am J Gastroenterol. 2008;103:2043-2050.
    1. Gorard DA, Libby GW, Farthing MJ. Effect of a tricyclic antidepressant on small intestinal motility in health and diarrhea-predominant irritable bowel syndrome. Dig Dis Sci. 1995;40:86-95.
    1. Drossman DA, Tack J, Ford AC, Szigethy E, Tornblom H, Van Oudenhove L. Neuromodulators for functional gastrointestinal disorders (disorders of gut-brain interaction): a Rome Foundation working team report. Gastroenterology. 2018;154:1140-1171.e1.
    1. Ford AC, Lacy BE, Harris LA, Quigley EM, Moayyedi P. Effect of antidepressants and psychological therapies in irritable bowel syndrome: an updated systematic review and meta-analysis. Am J Gastroenterol. 2019;114:21-39.
    1. Ford AC, Marwaha A, Lim A, Moayyedi P. What is the prevalence of clinically significant endoscopic findings in subjects with dyspepsia? Systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2010;8:830-837.
    1. Eusebi LH, Black CJ, Howden CW, Ford AC. Effectiveness of management strategies for uninvestigated dyspepsia: systematic review and network meta-analysis. BMJ. 2019;367:l6483.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться